Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06018428 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
A Phase 2 study of Alopecia Areata, sponsored by Q32 Bio.
- Active
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 20
- Study locations
NCT06018428: Active Phase 2 study of Alopecia Areata, sponsored by Q32 Bio.
NCT06018428 is a Phase 2 study of Alopecia Areata that is active but no longer recruiting, run by Q32 Bio. The registered enrollment target is 75 participants, below the 1,952-participant average among 26 other Alopecia Areata trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06018428, a Phase 2 study of Alopecia Areata, is active but no longer recruiting, sponsored by Q32 Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation. Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempikibart (ADX-914) in participants with severe Alopecia Areata.
Primary Outcome
Part A: Mean relative percent change in SALT score at 24 weeks compared with baseline
Conditions Studied
Interventions
- DRUG bempikibart (ADX-914)
Study Locations (20)
California
- Encinitas, California - Encinitas
- Fountain Valley, California - Fountain Valley
- Lomita, California - Lomita
Ohio
- Bexley, Ohio - Bexley
- Clinical Trials - Canton
- Mason, Ohio - Mason
Arkansas
- Fayetteville, Arkansas - Fayetteville
- Hot Springs, Arkansas - Hot Springs
Florida
- Miami, Florida - Miami
- Tampa, Florida - Tampa
Michigan
- Troy, Michigan - Troy
- Warren, Michigan - Warren
New York
- New York, New York - New York
- New York, New York - New York
Arizona
- Scottsdale, Arizona - Scottsdale
Connecticut
- New Haven, Connecticut - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-09-12 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT06018428 still lists
NCT06018428 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 1,952-participant average among 26 other Alopecia Areata trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 1 intervention - of which bempikibart (ADX-914) is the first listed.
NCT06018428 names 20 study sites across 12 states, led by California, Ohio, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06018428 about?
NCT06018428 is a clinical study titled "A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)". Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation. Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempiki...
What is the current status of trial NCT06018428?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2023-09-12. Estimated completion is 2026-09.
What conditions does trial NCT06018428 study?
This clinical trial studies the following conditions: Alopecia Areata.
What interventions are being tested in trial NCT06018428?
The interventions under investigation include: bempikibart (ADX-914) (DRUG).
Who is sponsoring clinical trial NCT06018428?
This trial is sponsored by Q32 Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06018428 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06018428's enrollment target sits among peer trials
75 17th of 26 higher than 10 of 26 other Alopecia Areata trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alopecia Areata trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
A Study of LAD603 in Adults With Alopecia Areata
RECRUITING · Phase 2
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
RECRUITING · Phase 2
-
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
RECRUITING · Phase 2
-
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
RECRUITING · Phase 2
-
Regeneron AA Multicenter (Dupilumab)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI